Lancet accepts MMR study 'false,' as research leader found to have broken rules

3 February 2010

The prestigious British medical journal The Lancet, which originally published the discredited research linking autism and bowel disease and the childhood MMR (measles, mumps and rubella) vaccine - and which caused vaccination rates in the UK to plummet, resulting in a rise in measles - has now issued a full retraction of the paper. The Lancet said it now accepted claims made by the researchers were "false."

The move comes after Andrew Wakefield, the lead researcher in the 1998 paper, was ruled last week to have broken research rules by the General Medical Council. Last week, the GMC ruled that Dr Wakefield had shown a "callous disregard" for children and acted "dishonestly" while he carried out his research. It will decide later whether to strike him off the medical register. Immunization rates plunged in the U.K. to less than 80% by 2003.

The retraction by The Lancet comes a day after a competing publication, The British Medical Journal, issued an embargoed commentary calling for The Lancet to formally retract the study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical